Lenalidomide plus dexamethasone for previously untreated multiple myeloma

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Final draft guidance

Final appraisal document (PDF 267 KB)

Committee papers (PDF 7.62 MB)

Public committee slides (PDF 914 KB)

Final scope (PDF 82 KB)

Final matrix (PDF 90 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 109 KB)

Equality impact assessment (Scoping) (PDF 80 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: draft scope - April 2015 (PDF 33 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: provisional matrix - April 2015 (PDF 25 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: equality impact assessment - scoping (PDF 56 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: final scope (PDF 52 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: final matrix (PDF 51 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: draft scope for consultation (pre-referral) - March 2011 (PDF 78 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: provisional matrix (pre-referral) - March 2011 (PDF 59 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: consultees and commentators comments on draft scope (PDF 126 KB)

Multiple myeloma (newly diagnosed) - lenalidomide: consultees and commentators comments on provisional matrix (PDF 41 KB)